The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Imidazolone     3,5-dihydroimidazol-4-one

Synonyms: Imidazolinon, IMIDAZOLINONE, imidazol-4-one, SureCN16233, SureCN181499, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of C06195


High impact information on C06195


Chemical compound and disease context of C06195


Biological context of C06195


Anatomical context of C06195


Associations of C06195 with other chemical compounds


Gene context of C06195

  • Serum CML and imidazolone levels fell significantly in balance-treated patients [7].
  • Then we determined the localization of imidazolone in the amyloid tissues by immunohistochemistry using the antibody [3].
  • 3-DG accumulating in uremic serum may be involved in the modification of beta 2m with imidazolone [3].
  • Affinity purification of AGE-modified proteins from IC and immunoblotting with antibodies against Ig gamma and mu heavy chains, kappa and lambda light chains, and AGE Nepsilon(carboxymethyl)lysine and imidazolone yielded similar results: anti-AGE+ RA patients had elevated levels relative to those without the autoantibody [20].
  • METHODS: Immunohistochemical localisation of N(epsilon)-(carboxymethyl)-l-lysine (CML), N(epsilon)-(carboxyethyl)-l-lysine (CEL), pyrraline, pentosidine and imidazolone was examined in three corneas with CDK, six corneas with bullous keratopathy and three corneas without any corneal diseases [5].

Analytical, diagnostic and therapeutic context of C06195

  • The formation of late glycation products was assessed by fluorescence spectroscopy and Western blotting that used a specific antibody for imidazolone, a late glycation product [21].
  • To determine if 3-DG is involved in the formation of intracellular AGEs, we measured the erythrocyte levels of 3-DG and AGEs such as imidazolone and N epsilon-carboxymethyllysine (CML) in hemodialysis (HD) patients with diabetes [16].
  • Liquid chromatography/mass spectrometry demonstrated that the formation of imidazolone A by incubating 3-DG with arginine is very rapid, reaching a maximum concentration within 24 h, but the formation of imidazolone B is very slow and low in quantity even after 2 weeks [8].
  • In conclusion, the accumulation of imidazolone was noted in peritoneal tissues of CAPD patients, which preceded a decrease in UF capacity [13].


  1. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. Niwa, T., Katsuzaki, T., Miyazaki, S., Miyazaki, T., Ishizaki, Y., Hayase, F., Tatemichi, N., Takei, Y. J. Clin. Invest. (1997) [Pubmed]
  2. Piroximone, dobutamine and nitroprusside: comparative effects on haemodynamics in patients with congestive heart failure. Baumann, G., Ningel, K., Vieweg, J., Joder-Ohlenbusch, A.M., Cremer, G. Eur. Heart J. (1991) [Pubmed]
  3. Amyloid beta 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis. Niwa, T., Katsuzaki, T., Miyazaki, S., Momoi, T., Akiba, T., Miyazaki, T., Nokura, K., Hayase, F., Tatemichi, N., Takei, Y. Kidney Int. (1997) [Pubmed]
  4. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Henle, T., Deppisch, R., Beck, W., Hergesell, O., Hänsch, G.M., Ritz, E. Nephrol. Dial. Transplant. (1999) [Pubmed]
  5. Advanced glycation end product deposits in climatic droplet keratopathy. Kaji, Y., Nagai, R., Amano, S., Takazawa, Y., Fukayama, M., Oshika, T. The British journal of ophthalmology (2007) [Pubmed]
  6. Immunochemical detection of imidazolone in uremia and rheumatoid arthritis. Franke, S., Niwa, T., Deuther-Conrad, W., Sommer, M., Hein, G., Stein, G. Clin. Chim. Acta (2000) [Pubmed]
  7. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Williams, J.D., Topley, N., Craig, K.J., Mackenzie, R.K., Pischetsrieder, M., Lage, C., Passlick-Deetjen, J. Kidney Int. (2004) [Pubmed]
  8. Imidazolone, a novel advanced glycation end product, is present at high levels in kidneys of rats with streptozotocin-induced diabetes. Niwa, T., Katsuzaki, T., Ishizaki, Y., Hayase, F., Miyazaki, T., Uematsu, T., Tatemichi, N., Takei, Y. FEBS Lett. (1997) [Pubmed]
  9. The objective and timing of drug disposition studies, appendix I. Species differences in the tissue distribution of metazimid, an imidazolone derivative. Zak, S.B., Weiner, M. Drug Metab. Rev. (1975) [Pubmed]
  10. Synthesis of axinohydantoins. Barrios Sosa, A.C., Yakushijin, K., Horne, D.A. J. Org. Chem. (2002) [Pubmed]
  11. UVR-induced G-C to C-G transversions from oxidative DNA damage. Kino, K., Sugiyama, H. Mutat. Res. (2005) [Pubmed]
  12. Nonoxidative protein glycation is implicated in familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation. Shibata, N., Nagai, R., Miyata, S., Jono, T., Horiuchi, S., Hirano, A., Kato, S., Sasaki, S., Asayama, K., Kobayashi, M. Acta Neuropathol. (2000) [Pubmed]
  13. Localization of imidazolone in the peritoneum of capd patients: a factor for a loss of ultrafiltration. Nakamura, S., Miyazaki, S., Sakai, S., Morita, T., Hirasawa, Y., Niwa, T. Am. J. Kidney Dis. (2001) [Pubmed]
  14. Formation of advanced glycation end products during CAPD. Tauer, A., Zhang, X., Schaub, T.P., Zimmeck, T., Niwa, T., Passlick-Deetjen, J., Pischetsrieder, M. Am. J. Kidney Dis. (2003) [Pubmed]
  15. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin. Lo, T.W., Westwood, M.E., McLellan, A.C., Selwood, T., Thornalley, P.J. J. Biol. Chem. (1994) [Pubmed]
  16. Increased erythrocyte 3-DG and AGEs in diabetic hemodialysis patients: role of the polyol pathway. Tsukushi, S., Katsuzaki, T., Aoyama, I., Takayama, F., Miyazaki, T., Shimokata, K., Niwa, T. Kidney Int. (1999) [Pubmed]
  17. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Busch, M., Franke, S., Müller, A., Wolf, M., Gerth, J., Ott, U., Niwa, T., Stein, G. Kidney Int. (2004) [Pubmed]
  18. The pH-dependent role of superoxide in riboflavin-catalyzed photooxidation of 8-oxo-7,8-dihydroguanosine. Luo, W., Muller, J.G., Burrows, C.J. Org. Lett. (2001) [Pubmed]
  19. Advanced glycation end-products in anterior chamber aqueous of cataractous patients. Franke, S., Stein, F., Dawczynski, J., Blum, M., Kubetschka, U., Stein, G., Strobel, J. Journal of cataract and refractive surgery. (2003) [Pubmed]
  20. An autoantibody targeting glycated IgG is associated with elevated serum immune complexes in rheumatoid arthritis (RA). Tai, A.W., Newkirk, M.M. Clin. Exp. Immunol. (2000) [Pubmed]
  21. Glucose-modified proteins modulate essential functions and apoptosis of polymorphonuclear leukocytes. Cohen, G., Rudnicki, M., Walter, F., Niwa, T., Hörl, W.H. J. Am. Soc. Nephrol. (2001) [Pubmed]
WikiGenes - Universities